Investigating the Spreading Uptake of Sacubitril/Valsartan Across the US
b'When new drugs are approved by the FDA, they can take time to diffuse across the population as clinicians begin to prescribe them. Uptake is not always quick or uniform, due to reasons that can include clinical inertia, provider familiarity, and the cost to patients. \\n\\nOn this episode of Managed Care Cast, we\\u2019re talking with the lead author of a study published in our December 2021 issue. The article, \\u201cVariation in Early Diffusion of Sacubitril/Valsartan and Implications for Understanding Novel Drug Diffusion,\\u201d describes how prescribing of the newly approved heart failure drug spread across the nation. Joining us today is Lauren Gilstrap, MD, MPH, of Dartmouth-Hitchcock Medical Center and The Dartmouth Institute for Health Policy and Clinical Practice.'